Skip to main content
S

Syngens

Syngens AS has developed an AI-powered DNA Design Platform that enables precise and predictable DNA engineering for biomanufacturing applications. By optimizing gene expression and constructing novel biological pathways, the platform addresses the limitations of scalability and engineering precision in current biological methods, significantly reducing trial-and-error in experimental processes.

Trondheim, NorwayFounded 20204200+ followers
Updated 20 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Current biomanufacturing methods face limitations in scalability and engineering precision, leading to significant trial-and-error in experimental processes and hindering the full potential of biology in addressing sustainability challenges. Optimizing gene expression and constructing novel biological pathways remains a complex and unpredictable task.

Solution

Syngens AS offers an AI-powered DNA Design Platform that enables precise and predictable DNA engineering for biomanufacturing applications. The platform leverages advanced algorithms to optimize gene expression, construct novel biological pathways, and design DNA sequences tailored to specific biomanufacturing needs. By bridging the gap between the complexity of biological systems and engineering precision, the platform reduces the need for extensive experimentation. Its predictive models computationally test and refine millions of designs, selecting only the most promising candidates for biological validation, accelerating time-to-market and ensuring superior outcomes in production efficiency.

Target Audience

The primary users are researchers and innovators in synthetic biology and biomanufacturing who seek to optimize gene expression, construct novel biological pathways, and improve production efficiency.

Features

  • AI-powered platform for precise and predictable DNA engineering
  • Multi-organism compatibility for diverse applications
  • Advanced codon optimization to enhance gene expression
  • De novo DNA design and optimization for novel constructs
  • Novel pathway engineering and refactoring for synthetic biology
  • Predictive models to test and refine millions of designs computationally
This profile is AI-generated and may contain inaccuracies.